Activation of PI3K-AKT-mTOR pathway has been reported to contribute to both intrinsic and acquired resistance to MAPK pathway inhibitors, which provides strong rationale for combinatory inhibition of MAPK and PI3K pathway in the treatment of RAS mutant cancer. The gene discussed is AKT1; the disease is cancer.